Erythropoietin: when liability becomes asset in neurovascular repair.
about
Analysis of circulating hem-endothelial marker RNA levels in preterm infants.Neurodegeneration: An early event of diabetic retinopathy.The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier--implications for the pathogenesis of diabetic retinopathy.Diabetic Retinopathy: Vascular and Inflammatory Disease.Growth Factors in the Pathogenesis of Retinal Neurodegeneration in Diabetes MellitusNeurodegeneration in diabetic retina and its potential drug targets.
P2860
Erythropoietin: when liability becomes asset in neurovascular repair.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Erythropoietin: when liability becomes asset in neurovascular repair.
@en
Erythropoietin: when liability becomes asset in neurovascular repair.
@nl
type
label
Erythropoietin: when liability becomes asset in neurovascular repair.
@en
Erythropoietin: when liability becomes asset in neurovascular repair.
@nl
prefLabel
Erythropoietin: when liability becomes asset in neurovascular repair.
@en
Erythropoietin: when liability becomes asset in neurovascular repair.
@nl
P2093
P2860
P356
P1476
Erythropoietin: when liability becomes asset in neurovascular repair.
@en
P2093
Alexander V Ljubimov
Maria B Grant
Michael E Boulton
P2860
P304
P356
10.1172/JCI34643
P407
P577
2008-02-01T00:00:00Z